Farrukh T Awan MD

Hematology•Dallas, TX

Hematologic Oncology

Associate Professor of Internal Medicine

Join to View Full Profile

6201 Harry Hines Blvd Mail Code 8Dallas, TX 75390
Phone+1 214-645-4673
Fax+1 214-645-2661

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2006 - 2009
UPMC Medical EducationResidency, Internal Medicine, 2003 - 2006
Aga Khan Medical CollegeClass of 2001

Certifications & Licensure

TX State Medical License 2018 - 2027
OH State Medical License 2006 - 2019
GA State Medical License 2009 - 2014
American Board of Internal Medicine Hematology

Clinical Trials

Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia Start of enrollment: 2010 Sep 01
Completed
Phase 1
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2011 Nov 02
ACTIVE_NOT_RECRUITING
PHASE2
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2016 Jan 12
ACTIVE_NOT_RECRUITING
PHASE2
Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL Start of enrollment: 2015 Nov 09
Terminated
Phase 1, Phase 2
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) Start of enrollment: 2020 Nov 18
Suspended
Phase 1, Phase 2
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) Start of enrollment: 2019 Jul 22
TERMINATED
PHASE1, PHASE2
Roles: Contact
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2017 Nov 27
RECRUITING
PHASE1, PHASE2
Roles: Principal Investigator, Contact
DALY II USA/ MB-CART2019.1 for DLBCL Start of enrollment: 2021 May 25
RECRUITING
PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inh...
Mary Ann Anderson, Farrukh T Awan, Leanne Berkahn, Kyle Crassini, Hui-Peng Lee
Internal Medicine Journal. 2025-09-01
1 citations
Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis.
Miguel-Angel Perales, Farrukh T Awan, Ariane Boumendil, Jinalben Patel, Luca Castagna
Blood. 2025-08-21
New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma.
Uri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, Soyoung Kim, Amy Moskop
Blood Advances. 2025-08-14

Abstracts/Posters

Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL
Farrukh T. Awan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
Farrukh T Awan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy
Farrukh T. Awan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Farrukh T. Awan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic Leukemia
Farrukh T. Awan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL
Farrukh T. Awan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting
Farrukh T. Awan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Press Mentions

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical CenterMay 6th, 2025
The IntersectionFebruary 1st, 2022
Lymphoma Research Foundation to Host Nationwide Virtual RallyApril 28th, 2020
Join now to see all